Sotera Health (NASDAQ:SHC) Receives $16.92 Average Target Price from Analysts

Shares of Sotera Health (NASDAQ:SHC) have been assigned an average rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $16.92.

A number of brokerages have recently commented on SHC. Jefferies Financial Group raised Sotera Health from a “hold” rating to a “buy” rating and increased their price objective for the company from $15.00 to $15.50 in a report on Monday, March 25th. TheStreet upgraded Sotera Health from a “d” rating to a “c-” rating in a research note on Tuesday, February 27th. Barclays decreased their target price on Sotera Health from $19.00 to $14.00 and set an “overweight” rating for the company in a research note on Wednesday, April 10th. Royal Bank of Canada restated an “outperform” rating and set a $20.00 target price on shares of Sotera Health in a research note on Monday, March 4th. Finally, Citigroup upgraded Sotera Health from a “neutral” rating to a “buy” rating and decreased their target price for the company from $18.00 to $16.00 in a research note on Wednesday, April 3rd.

Sotera Health Stock Performance

Shares of NASDAQ SHC opened at $12.01 on Monday. The company has a debt-to-equity ratio of 5.39, a quick ratio of 2.86 and a current ratio of 3.20. The firm has a market cap of $3.40 billion, a price-to-earnings ratio of 63.21 and a beta of 2.05. The business’s 50-day simple moving average is $11.36 and its 200-day simple moving average is $13.54. Sotera Health has a 52 week low of $10.71 and a 52 week high of $19.40.

Sotera Health (NASDAQ:SHC) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.01). The company had revenue of $248.18 million for the quarter, compared to analyst estimates of $254.73 million. Sotera Health had a net margin of 5.09% and a return on equity of 48.47%. As a group, equities research analysts expect that Sotera Health will post 0.63 earnings per share for the current fiscal year.

Institutional Trading of Sotera Health

A number of hedge funds have recently modified their holdings of the company. DekaBank Deutsche Girozentrale bought a new position in shares of Sotera Health during the 3rd quarter worth approximately $58,000. Sandia Investment Management LP bought a new position in shares of Sotera Health during the 1st quarter worth approximately $120,000. Securian Asset Management Inc. lifted its position in shares of Sotera Health by 23.0% during the 1st quarter. Securian Asset Management Inc. now owns 10,178 shares of the company’s stock worth $122,000 after buying an additional 1,900 shares during the period. Quest Partners LLC bought a new position in shares of Sotera Health during the 4th quarter worth approximately $139,000. Finally, State of Alaska Department of Revenue lifted its position in shares of Sotera Health by 20.6% during the 1st quarter. State of Alaska Department of Revenue now owns 13,490 shares of the company’s stock worth $162,000 after buying an additional 2,300 shares during the period. Institutional investors own 91.03% of the company’s stock.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.